Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

• Harma Alma,
• Harma Alma,
• Corina de Jong,
• Corina de Jong,
• Janwillem Kocks,
• Janwillem Kocks,
• Janwillem Kocks,
• Thys van der Molen,
• Thys van der Molen

Affiliations

Harma Alma

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Harma Alma

GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Corina de Jong

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Corina de Jong

GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Janwillem Kocks

GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Janwillem Kocks

General Practitioners Research Institute, Groningen, Netherlands

Janwillem Kocks

Observational and Pragmatic Research Institute, Singapore, Singapore

Thys van der Molen

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Thys van der Molen

GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, Netherlands